1.	Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: CH-BC-008, NCT01143974
2.	Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Phase: Phase IV Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: BD-IC-IV08, NCT01665417
3.	Mesothelioma Avastin Plus Pemetrexed-cisplatin Study Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: IFCT-GFPC-0701, NCT00651456
4.	Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TG4010.14/TIME, 8559, NCT01383148
5.	Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CIKLC-201004, NCT01481259
6.	Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy Phase: Phase III, Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: D7913L00077, NCT01579630
7.	Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00509, U10CA021115, CDR0000475774, E1505, ECOG-E1505, SWOG-E1505, CALGB-E1505, CAN-NCIC-E1505, NCCTG-E1505, NCT00324805
8.	Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11514, H3E-MC-JMIG, NCT00686959
9.	A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9707, H3E-MC-JMHD, NCT00762034
10.	ERCC1 Targeted Trial Phase: Phase III Type: Health services research, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ISRCTN02370070, CRUK-UCL-ET, EUDRACT-2007-007639-17, ET TRIAL, NCT00801736
11.	An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A8081007, NCT00932893
12.	Study of Patients With Advanced Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13258, H3E-US-S130, NCT00948675
13.	Phase III Randomized Study of Proteomic Profiling in Predicting Efficacy of Second-Line Erlotinib Hydrochloride Versus Standard Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SRSI-HSRL-02-2007, HSRL-02-2007, PROSE, 2007-006299-13, EU-20975, NCT00989690
14.	Phase III Randomized Study of Gemcitabine Hydrochloride or Pemetrexed Disodium in Combination With Carboplatin With Versus Without Celecoxib in Patients With COX-2-Expressing Advanced Non-Small Cell Lung Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-30801, CALGB-30801, NCT01041781
15.	Phase III Randomized Study of Maintenance Therapy Comprising Bevacizumab Versus Pemetrexed Disodium Versus Bevacizumab and Pemetrexed Disodium Following Induction Therapy With Carboplatin, Paclitaxel, and Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E5508, E5508, NCT01107626
16.	A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A8081014, NCT01154140
17.	Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 99-1896C, NCT01204307
18.	Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a "Classical" Strategy of Treatment Allocation, With an"Optimized" Strategy Allocating the Same Treatments Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: 70 and over Sponsor: Other Protocol IDs: EudraCT 2008-008372-13, NCT01257139
19.	TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: DOCET_L_05478, NCT01282151
20.	Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum Phase: Phase III Type: Supportive care Status: Active Age: 30 and over Sponsor: Pharmaceutical / Industry Protocol IDs: G300505, POWER2, NCT01355497
21.	A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-302, NCT01454934
22.	A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D791LC00001, NCT01544179
23.	Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 70 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: AMC 2011-0857, NCT01593293
24.	Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: IFCT-GFPC-1101, NCT01631136
25.	A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: A8081029, NCT01639001